@[email protected] http://OncologyTube.com had the pleasure of speaking with Dr. Kaklamani about Elacestrant.
https://oncologytube.com/v/41478
🐦🔗: https://twitter.com/oncologytube/status/1620116074338607104
Philippe Aftimos
- 33 Followers
- 54 Following
- 81 Posts
Medical oncologist at Institut Jules Bordet in Brussels. Breast cancer, clinical research, Union Saint-Gilloise 💛💙, music, photography, poetry, in no particular order. Born in Lebanon 🇱🇧, Belgian (Brussels) 🇧🇪 by choice.
In Annals of Oncology, a report on the STING (NCT04932525) study in which patients with advanced cancer had molecular profiling using a ctDNA sequencing assay 🩸🧬 and were assigned matched therapy 💊 as per a molecular tumor board. https://www.annalsofoncology.org/article/S0923-7534(23)00046-7/fulltext
@[email protected] @[email protected]
🐦🔗: https://twitter.com/Annals_Oncology/status/1619997528812048385
The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?
🐦🔗: https://twitter.com/VKaklamani/status/1619858718467985408
VIRGINIA KAKLAMANI on Twitter
“The approval of #elacestrant for #mbc opens up a debate about the fda approval process. A clear benefit in esr1m tumors and at least equivalence in nonmutated. But oral therapy with mostly grade 1 and 2 toxicity. So why can’t physicians and patients have another oral option?”
The #OncoAlertColloquium 🚨Pls SHARE‼️
Day1⃣ #BreastCancer
https://youtu.be/T1mXJjGJRN4
Day2⃣GU Onc
https://youtu.be/Ph8BfNDM9Qk
Day3⃣ #LungCancer
https://youtu.be/XxcFJd5CJ8M
Day4⃣ #GynOnc
https://youtu.be/25BwcEBKo-E
Day5⃣GI Onc
https://youtu.be/r0a913rSge0
Day6⃣Nursing
https://youtu.be/Our4DpN1Dqc
🐦🔗: https://twitter.com/OncoAlert/status/1619406322600120320
The 2022 OncoAlert Colloquium DAY 1: Breast Cancer
FDA approves elacestrant, oral SERD, for ESR1-mutated ER+ metastatic breast cancer, based on phase 3 EMERALD clinical trial. Last endocrine therapy approved was ~ 20 years ago. #bcsm @[email protected] Link to article and label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf https://ascopubs.org/doi/pdf/10.1200/JCO.22.00338?role=tab
🐦🔗: https://twitter.com/dradityabardia/status/1619074675186999297
Elacestrant approved for esr1m mbc. A journey that started from the phase 1 trial here at @[email protected] with the collaboration of Aditya Bardia to the phase 3 EMERALD trial showing significant improvement compared with soc et. @[email protected] @[email protected]
🐦🔗: https://twitter.com/VKaklamani/status/1619074478692257792
A first oral SERD @[email protected] approval! More convenient administration schema & efficacy data in the ESR1m setting.
A huge thanks to the patients that participated in the clinical trials and their families. I feel humbled and privileged for taking part in the development #bcsm
A huge thanks to the patients that participated in the clinical trials and their families. I feel humbled and privileged for taking part in the development #bcsm
We are delighted to host today at @[email protected] Dr Barbara Pistilli (@[email protected] ) from @[email protected] for a talk on antibody-drug conjugates in the Meet the Oncology Expert seminar
In Annals of Oncology, genomic characterization 🧬of HR+ breast cancer in very young women enrolled in SOFT shed light on unfavourable prognostic features potentially informing future therapeutic strategies
https://www.annalsofoncology.org/article/S0923-7534(23)00047-9/fulltext
@[email protected] @[email protected] #bcsm
🐦🔗: https://twitter.com/Annals_Oncology/status/1618653748636823554
DAY1⃣ #OncoAlertColloquium 🚨
2022 in #breastcancer
NOW ON DEMAND‼️
@[email protected] 🇺🇸
@[email protected] 🇺🇸
@[email protected] 🇮🇹
@[email protected] 🇺🇸
@[email protected] 🇺🇸
@[email protected] 🇮🇹
@[email protected] 🇬🇧
@[email protected] 🇧🇪
@[email protected] 🇺🇸
LINK (COPY, PASTE, SHARE🌐)
https://www.youtube.com/watch?v=T1mXJjGJRN4
🐦🔗: https://twitter.com/OncoAlert/status/1617624182577332226